Natalie J. Torok, M.D., M.Sc.
Gastroenterology and Hepatology
UC Davis Medical Group
- Professor, VA Northern California Health Care System, Mather, CA
UC Davis Medical Group - Sacramento (J Street)
2825 J St., Suite 400
Sacramento, CA 95816
UC Davis Medical Group - Folsom
271 Turn Pike Dr.
Folsom, CA 95630
Additional Phone Numbers
Physician Referrals: 800-4-UCDAVIS (800-482-3284)
Philosophy of Care
As a hepatologist and certified transplant hepatologist, I take care of patients with end-stage liver disease and also provide post-transplant care, including management of immunosuppression and treatment of post-transplant hepatitis C.
I see patients with nonalcoholic steatohepatitis (NASH), alcoholic liver disease, and autoimmune hepatitis. Also, we provide comprehensive care for patients with hepatocellular carcinoma.
Dr. Torok's clinical interests include; Gastroenterology and Hepatology, Transplant Hepatology, and Internal Medicine.
Our research focuses on wound healing and the basic mechanism of fibrosis in the liver. We explore the pathways linking chronic liver injury, hepatocyte death and the activation of hepatic stellate cells, the principle fibrogenic cells of the liver.
Our investigations led to the discovery of the important role of the NADPH oxidases in stellate cell activation and the production of oxidative radicals. Based on our findings our aim is to explore the specific role of NADPH oxidases in non-alcoholic steatohepatitis and alcoholic liver disease. Our ultimate goal is to move towards translational studies and to develop new therapies for patients with liver fibrosis and cirrhosis.
Gastroenterology and Hepatology
M.D., Semmelweis Medical University, Budapest, 1988
M.Sc., Cellular and Molecular Biology, Cancer Research Institute of Laval University, Quebec Canada 1992
B.Sc., Verseghy Gimnázium, Szolnok Hungary 1982
Semmelweis University , Budapest , 1988-1990
Internal Medicine, Mayo Clinic , Rochester MN 1996-1999
Gastroenterology and Hepatology, Mayo Clinic , Rochester MN 1999-2003
American Board of Internal Medicine, 2010
American Board of Internal Medicine, Gastroenterology and Hepatology, 2014
American Board of Internal Medicine, Transplant Hepatology, 2008
American Association for the Study of Liver Disease
American College of Physicians
American Gastroenterlogical Association
American Liver Foundation
American Society for Clinical Investigation
Honors and Awards
Associate Editor, American Journal of Physiology, Gastrointestinal and Liver Physiology, 2015
Elected to the American Society for Clinical Investigation, 2014
Boris Ruebner and John Rosenquist Excellence in Teaching Award, UC Davis, GI and Hepatology, 2014
Richard C. Woodard Award, UC Davis Mentor, 2014
Internal Medicine-Pathology-Surgery Research Award, UC Davis, 2012
University of California, Cancer Research Coordinating Committee Award, 2006
Select Recent Publications
Torok NJ: Update on Alcoholic Hepatitis. Biomolecules, 2015 Nov 2;5(4):2978-86.
Bettaieb A, Jiang JX, Sasaki Y, Chao TI, Kiss Z, Chen X, Tian J, Katsuyama M, Yabe-Nishimura C, Xi Y, Szyndralewiez C, Schröder K, Shah A, Brandes RP, Haj FG and Török NJ: “Hepatocyte NADPH Oxidase 4 Regulates Stress Signaling, Fibrosis, and Insulin Sensitivity during Development of Steatohepatitis in Mice”, Gastroenterology, 2015;Aug;149(2):468-480.
Torok NJ, JA. Dranoff, D. Schuppan and SL. Friedman: “Strategies and Endpoints of Antifibrotic Drug Trials” Hepatology, 2015;Aug;62(2):627-34.
Jiang JX, Torok NJ: ” MLK3 as a regulator of disease progression in NASH”. Liver Int. 2014 Apr 1.
Jiang XJ, Chen, X, Fukada, H, Serizawa, N, Devaraj, S, and Török, NJ: Advanced glycation end products induce fibrogenic activity in NASH by modulating the TNF? converting enzyme activity in mice. Hepatology, 2013, Oct;58(4):1339-48.